Member Info for biffa

It looks like Manchester is going to get blanket surge testing rather than any further lockdown.
Avacta down the road and Medusa 19 HQ right in the middle of it.
Really quite pathetic if we can't get involved in this.
FFS, what is the point of FTI?

Once PDSB release the next vaccine update the first bids will come in at $1B +. Might get lucky and a bidding war will take it to $1.5B+
NSCI value £50M+
ProAxis has the global rights to AZ anti body test which will be needed for everyone pre booster vaccine.
NSCI value £50M+
Glycotest is in the books at £11M. Trial news and sales ramp up expected within weeks. If positive this is a multi million $ market going forward.
NSCI value £50M+
So sell now at a £25M market cap or wait 3 to 6 months and take £150M market cap.

Zero coverage as far as I can see. Might be part of the master plan but a real shame for a great British biotech company to have the best LFT in the world and noone gives a fuuk!

2 owners hold close to 50% of this and they have waited a long time for the market to wake up to the value.
Advisors might want fees but i doubt they will sh@t on their doorstep just when things are getting interesting.

If anyone doesn't know, ProAxis all ready has Neatstik products on the market at £25 a test.

See our NEATstik® Neutrophil Elastase Airways Test leaflet for full details

NEATstik® is a rapid point-of-care test, which allows the monitoring of active neutrophil elastase levels in sputum samples.

NEATstik® is usually supplied in boxes of 10 tests. If required, a single test can be provided at a cost of £28 plus shipping and VAT (if applicable) Box of 10 is £250

If you’d like further details on NEATstik®, please contact us via info@proaxsis.com

The research team at AstraZeneca have already completed significant optimisation and validation work, which has demonstrated the assay's high potential sensitivity and specificity of detecting SARS-CoV-2 antibodies.

The development of this serology ELISA by our team is another example of AstraZeneca's comprehensive response to the COVID-19 pandemic. This highly sensitive and specific blood test makes use of simple and convenient fingerstick sample collection that will be well suited to large scale deployment and has the potential to play an important role in antibody analyses in large populations."

ProAxsis will take responsibility for completing the validation and global commercialisation of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA (enzyme-linked immunosorbent assay) developed by an internal research team at AstraZeneca. In return for providing access to the required intellectual property and technical know-how, AstraZeneca will receive an undisclosed royalty fee on future Global net sales of the assay.

AZ have all ready done 90% of the work and ProAxis have the test IP ready to go.

World wide product at a potential £25 a test, ready in a matter of weeks.

I might have to upgrade my £15 a share target.

Must be a 'D' notice on this in the UK press because there is fook all news out there.

Avacta PR get a fooking grip and get this story out.

We all know that booster vaccines are on there way for September and probably yearly.

This finger prick test will basically tell you when you need that top up jab.

Quite bloody brilliant and simple and will make us millions.

(not a bad advert for Proaxis tech)

Once validated and on the market you can slap a £50M+ price tag on Proaxis.

Glyotest news due this month.

PDSB ever upwards.

£15 a share by xmas.

If, like me,you have been here from the start you will remember how Han****/BBC cleared the airways when that rubbish DNA Nudge test appeared last September. A quite unbelievable amount of leaks and back door press invitations.
Then about 6 weeks ago Innova had half of the Sunday Times business front page to promote their rubbish.
Avacta have to wise up to the game and get this news out, across all channels.
I haven't seen anything yet apart from that link to that 10 year old reporter!

Interesting couple of months. Nice to see a few more investors join us.
We should get a decent update on Glycotest in June, which could go some way to doubling the SP.
I still think PDSB will get taken out for $1B+ which would give us a SP of £3.50+

Have to assume a decent note will come out alongside tomorrows LFT news.

We haven't had a new investor go over 3% for over a year. Lets hope that's about to change.

I think it's more the direction of LFT travel that's important.

'A test a day keeps Covid away'

All NHS Trusts are all ready 'gaming' this winters resurgence.

Lock down no longer a political option.

Has to be one of the best interviews i've seen for quite a while.
Quite why we are at 6/7p and not mid teens is beyond me.
The IP has to be worth the MCap on it's own.

PS. Stt, p*ss off you sad ******.

Quite an interesting hour.

I assume the BOD will have bought a few 100K on Friday. Either that or take a pay cut!

Anyone remember DNANudge from last Aug/Sept

The government has placed a £161 million order for 5.8 million high-speed DnaNudge COVID-19 test kits to be used in NHS hospitals from September.

This major order will see DnaNudge’s lab-free, rapid and reliable PCR test, which delivers results in under 90 minutes and can work in about an hour, rolled out nationally in urgent patient care and elective surgery settings, with further deployments in out-of-hospital settings.

I am hugely grateful to DnaNudge and their incredible work to innovate coronavirus testing, which will mean we can test millions more people in the coming months.
Matt Han**** MP
Health Secretary
DnaNudge, an Imperial startup headquartered in White City, recently obtained a CE mark for its COVID Nudge test, enabling its additional use in non-clinical locations, including care homes and other public emergency services.

All leaked to the press on Sunday and was the main BBC news Monday morning. Han****, gamechanger etc etc.

Anyway, they did a private cash raise which valued them at £1.2B all on the back of the above. No cure for cancer, no joint ventures, no $300M jt funding etc etc.

Now we have the real deal and a chance to make this the last ever lockdown because we can now contain any outbreaks from day one.

All things being equal we should be north of £5.00 by the end of the week.

Which broker?

The company are happy to confirm that assets under the Netscientific Plc umbrella are worth in excess of £20M, against todays MCap of £8M. (PDSB @ $5.50)

The company are fully aware of the disconnect between the SP and NAV.

Walbrook PR have been appointed to raise the investor profile of the company with an aim of reducing this inconsistency.

A year end trading update is expected.

The company is happy to engage with private shareholders.

Our investment in PDSB equates to our entire MCap.
The rest of the portfolio worth another £1.00 a share.
Market asleep on this one.

About time Finncap/Stifel and perhaps FTI did their job and advised.
There is no way on earth Avacta will be an 'orderly' market tomorrow without some sort of update or clarification
on wtf is going on, NDA's or not.
I can't believe anyone really thinks any different so tick it up.

If you have a look at the results and placing docs you come up with a slightly better NAV than the current SP. A lot will depend on PDSB, but as we stand this evening.

A couple of things to remember.

Only 15M shares in issue
Recent placing at 65p to buy EMV Capital.
Concert party hold more than 50% of the shares so limited free float if it starts to move.

EMV Capital portfolio £3.4M
Cash £1.5M
3 main holdings £1.1M (Cyto,Edibone,G-Tech)
Glycotest £5.0M (more now as we hold a higher %)
PDSB £3.25M @ $3.00 a share.
£14.25M
I can't find a value for Proaxis, 100% owned, but as it just won a £300K grant and has new sales deals for USA and a few other areas, lets say £3M.

Add in todays PDSB rise, which is another £650K and you get close to £18M.

M Cap today less than £7M.

PDSB has some near term news flow due over the next few months which could send it parabolic.

Discuss!

Now the insiders have taken their profits the SP is moving up nicely as investors realize how undervalued it is.
They released a new updated presentation which is worth a read.
Back to NSCI.
Assets worth £14.25M plus 100% Proaxis and rising.
M Cap £6.7M
A massive value disconnect if ever I saw one.